Return to Index
Medications for Obesity
- Reduced caloric intake
- Regular exercise and other behavior changes
- Psychological counseling (if needed)
- Phentermine (Profast, Fastin, Ionamin, Adipex-P)
- Phendimetrazine (Bontril)
- Diethylpropion (Tenuate, Dospan)
- Phentermine plus extended release topiramate (Qsymia)
- Lorcaserin (Belviq)
Phentermine plus extended release topiramate
- Elevation of blood pressure
- Heart problems
- Nervousness or irritability
- Numbness or tingling of skin
- Change in taste
- Dry mouth
- Back pain
- Xenical (prescription)
- Alli (over-the-counter)
- Staining of underwear
- Pressure to empty bowels
- Leakage of stool
- Increased frequency of bowel movements
- Severe liver damage (rare side effect)
Over-the-Counter (OTC) Medications
- Take your medicine as directed. Do not change the amount or the schedule.
- Do not stop taking them without talking to your doctor.
- Do not share them.
- Know what the results and side effects. Report them to your doctor.
- Some drugs can be dangerous when mixed. Talk to a doctor or pharmacist if you are taking more than one drug. This includes over-the-counter medicine and herb or dietary supplements.
- Plan ahead for refills so you don’t run out.
Arterburn DE, Crane PK, Veenstra DI. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
Facts and comparisons. Drug Facts and Comparisons . 56th ed. St. Louis, MO: Facts and Comparisons; 2001.
Haddock CK, Poston WSW, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Meta Disord. 2002;26:263-273.
Li Z, Maglione M, Mojica W, Arterburn D, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
Obesity in adults. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php . Updated August 16, 2012. Accessed August 28, 2012.
Obesity in children and adolescents. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php . Updated July 25, 2012. Accessed August 28, 2012.
Phentermine. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php . Updated December 14, 2011. Accessed August 28, 2012.
Prescription medications for the tretment of obesity. National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://win.niddk.nih.gov/publications/prescription.htm#meds . Accessed August 28, 2012.
Snow V, Barry P, Fitteman N, Qaseem A, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guidelines from the American College of Physicians. Ann Intern Med. 2005;142:525-531.
Weight loss medications for obesity in adults. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/ . Updated July 18, 2012. Accessed August 28, 2012.
Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA . 2001;286:1331-1339.
11/20/2009 DynaMed's Systematic Literature Surveillance DynaMed's Systematic Literature Surveillance : Pai You Guo, marketed as dietary supplement—recall. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190531.htm . Published November 13, 2009. Accessed November 20, 2009.
1/22/2010 DynaMed's Systematic Literature Surveillance DynaMed's Systematic Literature Surveillance : Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm . Published January 21, 2010. Accessed January 22, 2010.
5/28/2010 DynaMed's Systematic Literature Surveillance DynaMed's Systematic Literature Surveillance : Orlistat (marketed as Alli and Xenical): labeling change. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213448.htm . Published March 26, 2010. Accessed March 28, 2010.
9/17/2010 DynaMed's Systematic Literature Surveillance DynaMed's Systematic Literature Surveillance : James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.
10/15/2010 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php : US Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm . Published October 8, 2010. Accessed October 15, 2010.
- Reviewer: Brian Randall, MD
- Review Date: 09/2012
- Update Date: 03/18/2013